Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|January 4, 2018

IFPAC Conference Program Highlights Advanced Manufacturing Science in Biopharma

The IFPAC annual meeting on advancing the understanding and control of manufacturing processes using process analytical technology will be held Feb. 11-14, 2018.

The IFPAC annual meeting on advancing the understanding and control of manufacturing processes using process analytical technology (PAT) will be held Feb. 11–14, 2018 in North Bethesda, MD. For more than 30 years, IFPAC has been a platform for sharing innovative ideas and information to help companies improve the way they manufacture quality products while maintaining global competitiveness, note the conference organizers. This year’s lineup of sessions, roundtables, panel discussions, workshops, poster sessions, and an exhibition will have an increased emphasis on advanced manufacturing science in the biotechnology and biopharmaceutical arenas.

Presenters include FDA and global leaders from industry and academia, and this year there is an increased focus on process control and real-time analytics in biopharmaceutical manufacturing with topics such as:

  • A novel, real-time adaptive process control system for optimized feeding of bioreactors

  • Integration of process analytical technologies in upstream bioprocessing

  • Enabling bioprocessing scale-up by means of in-line spectroscopy

  • Bioprocess Raman monitoring: overcoming the model-building rate-limiting step

  • Towards automated transfer of fed-batch culture processes between scales

  • Comparability and similarity for biotechnology products: a new approach

  • Smart sensors for bioprocessing.

Other sessions will look at quality by design and real-time release, PAT for continuous manufacturing, quality risk management, knowledge and control of materials during continuous manufacturing of solid doses, advanced separation systems, process Raman technology, emerging technologies for product design and delivery, chemometrics, the industrial Internet of Things, excipients, particle characterization, and more.

Source: IFPAC


Related to this article

The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.